Dutch interest group calls for excessive drug-pricing probe
An advocacy group has said it will ask the Netherlands’ competition authority to investigate a drugmaker for setting excessive prices for the only drug that is available on the market for treating a rare genetic disease.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10